Quantcast
Home > Quotes > SCYX
SCYX

SCYNEXIS, Inc. Common Stock (SCYX) Quote & Summary Data

$1.65
*  
0.04
2.48%
Get SCYX Alerts
*Delayed - data as of Apr. 18, 2019  -  Find a broker to begin trading SCYX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 1.72 / $ 1.60
Share Volume
812,160
50 Day Avg. Daily Volume
887,719
Previous Close
$ 1.61
52 Week High / Low
$ 2.15 / $ 0.35
Market Cap
82,744,956
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
812,160
50 Day Avg. Daily Volume:
887,719

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.30

Trading Range

The current last sale of $1.65 is 371.43% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.72 $ 2.15
 Low: $ 1.60 $ 0.35

Company Description (as filed with the SEC)

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative therapies. We are developing our lead product candidate, ibrexafungerp (formerly SCY-078), as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including vulvovaginal candidiasis (VVC), invasive aspergillosis (IA), invasive candidiasis (IC), and refractory invasive fungal infections (rIFI). VVC, commonly known as "vaginal yeast infection," is the second most common cause of vaginitis and is usually caused by Candida species. IA is a serious fungal infection caused by Aspergillus species and is reported to be the leading cause of infection-caused death in immunocompromised patients.  ... More ...  



Risk Grade

Where does SCYX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.67
Open Date:
Apr. 18, 2019
Close Price:
$ 1.65
Close Date:
Apr. 18, 2019


Consensus Recommendation

Analyst Info